| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_132aa5ddba376cda52c2bedb26765245 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30 |
| filingDate |
2006-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4379aa83550cf05a3a24a1a07ff14d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b216fbfbaff1b5bcbcfbceba27d95f5 |
| publicationDate |
2007-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
PE-20061345-A1 |
| titleOfInvention |
PHARMACEUTICAL COMPOSITION INCLUDING SORAFENIB |
| abstract |
REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES ACID METHYLAMIDE 4- {4- [3- (4-CHLORO-3-TRIFLUOROMETHYLPHENYL) UREIDE] PHENOXY} PYRIDIN-2-CARBOXYL OR SORAFENIB (BAY 43-9006) AS A PRE-ACTIVE AGENT IF IN THE FORM OF SALT P-TOLUENOSULPHONIC ACID AS STABLE POLYMORPH I, IN A PORTION OF AT LEAST 40% BY WEIGHT OF THE COMPOSITION; A LOAD SUCH AS MICROCRYSTALLINE CELLULOSE IN A PORTION OF 0% TO 60% BY WEIGHT OF THE COMPOSITION; A DISGREGANT SUCH AS CROSCARMELOSE SODIUM IN A PORTION OF 0% TO 15% BY WEIGHT; A BINDER SUCH AS HYPROMELLOSE IN A PORTION OF 0% TO 15% BY WEIGHT; A LUBRICANT SUCH AS MAGNESIUM STEARATE WHICH IS IN A PORTION OF 0% TO 2% BY WEIGHT; AND A TENSIOACTIVE SUCH AS SODIUM LAURILSULFATE IN A PORTION OF 0% TO 5% BY WEIGHT OF THE COMPOSITION. IT ALSO REFERS TO A PREPARATION PROCEDURE. SAID COMPOSITION IS A SOLID ORAL PHARMACEUTICAL FORM, SUCH AS A PROLONGED RELEASE TABLET IN WHICH THE ACTIVE AGENT IS MICRONIZED AND IS AN INHIBITOR OF RAF KINASES, SO IT IS USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS LIKE TAL CANCER |
| priorityDate |
2005-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |